Keyphrases
Psoriasis
67%
Moderate-to-severe Psoriasis
66%
Psoriasis Severity
30%
Ustekinumab
30%
Area Index
29%
Severity Index
29%
Psoriasis Area
29%
Psoriatic Arthritis
25%
Ixekizumab
19%
Psoriasis Treatment
19%
Interleukin-17 (IL-17)
15%
Spain
13%
Clinical Trials
13%
Etanercept
13%
Brodalumab
12%
Dermatology Life Quality Index
12%
Atopic Dermatitis
11%
Quality of Life
11%
Secukinumab
11%
Psoriasis Disease
10%
Dermatologist
10%
Placebo
10%
Guselkumab
9%
Risankizumab
9%
Biological Treatment
9%
Biosimilar
9%
Europe
8%
Adalimumab
8%
Methotrexate
8%
Phase II Trial
8%
Clinical Practice
7%
Confidence Interval
7%
Pooled Analysis
7%
Pustular Psoriasis
7%
Long-term Efficacy
7%
Interleukin-23 (IL-23)
7%
Skin Diseases
7%
Long-term Safety
7%
Generalized Pustular Psoriasis
7%
Biological Agents
6%
Phase III Clinical Trial
6%
Plaque Psoriasis
6%
Immune-mediated Inflammatory Diseases
6%
Systemic Treatment
5%
Infliximab
5%
Comorbidity
5%
Itch
5%
Biologic Therapy
5%
Hidradenitis Suppurativa
5%
Moderate to Severe
5%
Pharmacology, Toxicology and Pharmaceutical Science
Psoriasis
100%
Psoriasis Vulgaris
38%
Ustekinumab
27%
Biological Product
21%
Psoriatic Arthritis
17%
Disease
15%
Clinical Trial
14%
Ixekizumab
13%
Adverse Event
12%
Etanercept
12%
Brodalumab
11%
Secukinumab
11%
Placebo
11%
Interleukin 17
11%
Methotrexate
9%
Risankizumab
9%
Atopic Dermatitis
7%
Guselkumab
7%
Pustular Psoriasis
6%
Adalimumab
6%
Cytokine
6%
Inflammatory Disease
5%
Infliximab
5%
Medicine and Dentistry
Psoriasis
74%
Psoriasis Vulgaris
25%
Biological Product
19%
Psoriasis Area and Severity Index
17%
Quality of Life
17%
Diseases
16%
Psoriatic Arthritis
12%
Ustekinumab
12%
Clinical Trial
12%
Dermatology Life Quality Index
11%
Ixekizumab
11%
Generalized Pustular Psoriasis
10%
Etanercept
10%
Dermatosis
10%
Dermatology
9%
Biosimilar
8%
Atopic Dermatitis
8%
Adverse Event
7%
Interleukin 17
7%
Inflammatory Disorder
7%
Immunity
7%
Comorbidity
6%
Pruritus
6%
Systemic Therapy
6%
Prevalence
5%
Cross Sectional Study
5%
Placebo
5%
Adalimumab
5%
Squamous Cell Carcinoma
5%
Risankizumab
5%